金陵藥業(000919.SZ)2020年度淨利潤預降52.52%-64.9%
格隆匯 1 月 26日丨金陵藥業(000919.SZ)公佈，預計2020年度歸屬於上市公司股東的淨利潤5100萬元-6900萬元，同比下降52.52%-64.90%；扣除非經常性損益的淨利潤6600萬元-8600萬元，同比增長56.29%-103.65%。業績變動原因如下：
1、2020年初，新冠肺炎疫情爆發。在抗疫期間，公司所屬四家醫院積極響應政府號召，投入各種醫療資源及醫護人員全力抗擊新冠肺炎疫情，醫院正常醫療工作受到影響，2020年上半年門急診及住院病人數均出現較大幅度下降，導致公司醫療服務業收入和利潤與上年同期相比都有一定幅度下降。
2、報吿期內公司預計非經常性損益對歸屬於上市公司股東的淨利潤的影響額約-1600萬元(上年同期影響額為10309.11萬元)，主要原因是江蘇紫金農村商業銀行股份有限公司(“紫金銀行”)股票公允價值變動收益變動所致。截止2020年12月31日，公司持有紫金銀行(股票代碼：601860)3529.643萬股，持股比例為0.96%。2020年12月31日，紫金銀行收盤價為4.21元/股,比上年末收盤價5.62元/股，下降1.41元/股，由此確認公允價值變動收益-4976.8萬元，由此減少歸屬於上市公司股東的淨利潤4230.28萬元。上年同期因持有紫金銀行確認公允價值變動收益增加歸屬於上市公司股東的淨利潤7440.49萬元。
3、國家醫藥衞生體制改革相關政策的頒佈與實施，對公司醫療板塊的相關業務產生較大影響，其中子公司南京鼓樓醫院集團儀徵醫院有限公司和湖州市社會福利中心有限公司2020年度淨利潤出現較大幅度下滑，基於此，公司對商譽進行了初步減值測試，出於謹慎性原則判斷，因收購南京鼓樓醫院集團儀徵醫院有限公司和湖州市社會福利中心有限公司所形成的商譽存在明顯的減值跡象，經公司財務部門及評估機構的初步測算，上述兩家公司計提商譽減值準備的金額預計在4000萬元-5000萬元之間，由此減少歸屬於上市公司股東的淨利潤預計在4000萬元-5000萬元之間。最終商譽減值準備計提的金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
